Hypoxia-targeting dendritic MRI contrast agent based on internally hydroxy dendrimer for tumor imaging

Han, Yuxin; Zhou, Xiaoxuan; Qian, Yue; Hu, Hongjie; Zhou, Zhuxian; Liu, Xiangrui; Tang, Jianbin; Shen, Youqing

doi:10.1016/j.biomaterials.2019.05.006

Cited by 35 publications

(26 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, the targeted and non‐targeted dendritic MR contrast agent had a relative longer blood circulation time ( t 1/2[α] = 1.06 and 0.55 hr, respectively) than that of Gd‐DTPA (5–6 min), but their Gd retention in major organs was as low as that of Gd‐DTPA. The above experiments indicated G3(DTPA‐Gd)‐SA at a 6.2 nm size was a relatively safe and potent contrast agent for MRI of tumors (Han et al, 2019).…”

Section: Applications Of Dendritic Nano‐scale Systems In Cancer Diagnmentioning

confidence: 97%

See 1 more Smart Citation

Recent advances in development of dendritic polymer‐based nanomedicines for cancer diagnosis

Sun

Zhu

et al. 2020

WIREs Nanomed Nanobiotechnol

162

View full text Add to dashboard Cite

Dendritic polymers have highly branched three‐dimensional architectures, the fourth type apart from linear, cross‐linked, and branched one. They possess not only a large number of terminal functional units and interior cavities, but also a low viscosity with weak or no entanglement. These features endow them with great potential in various biomedicine applications, including drug delivery, gene therapy, tissue engineering, immunoassay and bioimaging. Most review articles related to bio‐related applications of dendritic polymers focus on their drug or gene delivery, while very few of them are devoted to their function as cancer diagnosis agents, which are essential for cancer treatment. In this review, we will provide comprehensive insights into various dendritic polymer‐based cancer diagnosis agents. Their classification and preparation are presented for readers to have a precise understanding of dendritic polymers. On account of physical/chemical properties of dendritic polymers and biological properties of cancer, we will suggest a few design strategies for constructing dendritic polymer‐based diagnosis agents, such as active or passive targeting strategies, imaging reporters‐incorporating strategies, and/or internal stimuli‐responsive degradable/enhanced imaging strategies. Their recent applications in in vitro diagnosis of cancer cells or exosomes and in vivo diagnosis of primary and metastasis tumor sites with the aid of single/multiple imaging modalities will be discussed in great detail. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Diagnostic Tools > in vivo Nanodiagnostics and Imaging Diagnostic Tools > in vitro Nanoparticle‐Based Sensing

show abstract

Section: Applications Of Dendritic Nano‐scale Systems In Cancer Diagnmentioning

confidence: 97%

Section: Applications Of Dendritic Nano‐scale Systems In Cancer Diagnmentioning

confidence: 99%

Recent advances in development of dendritic polymer‐based nanomedicines for cancer diagnosis

Sun

Zhu

et al. 2020

WIREs Nanomed Nanobiotechnol

162

View full text Add to dashboard Cite

show abstract

“…In addition, the multivalent surface of dendrimers can significantly improve the relaxation of contrast agents and reduce the dosage of Gd, thus reducing the risk of metal poisoning in the human body [39]. Furthermore, macromolecular contrast agents can be used to passively target contrast agents to tumors [190]. At present, a variety of contrast agents have been developed that are based on dendrimers [191][192][193][194].…”

Section: Contrast Agentsmentioning

confidence: 99%

Safety Challenges and Application Strategies for the Use of Dendrimers in Medicine

Naeem

Xiao

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Dendrimers are used for a variety of applications in medicine but, due to their host–guest and entrapment characteristics, are particularly used for the delivery of genes and drugs. However, dendrimers are intrinsically toxic, thus creating a major limitation for their use in biological systems. To reduce such toxicity, biocompatible dendrimers have been designed and synthesized, and surface engineering has been used to create advantageous changes at the periphery of dendrimers. Although dendrimers have been reviewed previously in the literature, there has yet to be a systematic and comprehensive review of the harmful effects of dendrimers. In this review, we describe the routes of dendrimer exposure and their distribution in vivo. Then, we discuss the toxicity of dendrimers at the organ, cellular, and sub-cellular levels. In this review, we also describe how technology can be used to reduce dendrimer toxicity, by changing their size and surface functionalization, how dendrimers can be combined with other materials to generate a composite formulation, and how dendrimers can be used for the diagnosis of disease. Finally, we discuss future challenges, developments, and research directions in developing biocompatible and safe dendrimers for medical purposes.

show abstract

“…Hypoxia is one of the critical features in solid tumors, thus hypoxia-targeting contrast agents should enhance their specificity. It was shown that this dendrimer greatly enhanced the MRI of orthotopic breast tumor in a mouse model [65]. Two families of anionic linear globular dendrimers (ALGD) based on a polyethyleneglycol (PEG) core and biodegradable polyester dendritic branches on each extremity of the PEG have been synthesized.…”

Section: Dtpa Gd Complexes Of Other Dendrimersmentioning

confidence: 99%

Dendritic metal complexes for bioimaging. Recent advances

Caminade

Hameau

Turrin

et al. 2021

Coordination Chemistry Reviews

View full text Add to dashboard Cite

Dendrimers are hyperbranched macromolecules, having a large number of terminal functions, easily accessible and modifiable to afford the desired properties. Metal complexes of dendrimers are frequently used as catalysts in diverse reactions, but they can be used also as innovative biological tools. This review focusses on the recent advances (last 10 years) of dendritic metal complexes used for bioimaging, essentially in vivo. Three main domains will be covered. The first one concerns luminescent complexes for optical imaging (OI). The second one is the largest one; it concerns magnetic resonance imaging (MRI) contrast agents, mostly based on gadolinium complexes. The third and last domain concerns radioactive dendrimer complexes for single photon emission computed tomography (SPECT), and also for positron emission tomography (PET). Two main radionucleides are used in this context, technetium ( 99m Tc) and indium ( 111 In). Two types of ligands are generally used for all these complexes in the two last domains, diethylenetriaminepentaacetic acid (DTPA), and a cyclic analogue, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and some of their derivatives. These complexes have been used in many cases for in vivo imaging of cancerous tumors in mice or rats.

show abstract

Hypoxia-targeting dendritic MRI contrast agent based on internally hydroxy dendrimer for tumor imaging

Cited by 35 publications

References 37 publications

Recent advances in development of dendritic polymer‐based nanomedicines for cancer diagnosis

Recent advances in development of dendritic polymer‐based nanomedicines for cancer diagnosis

Safety Challenges and Application Strategies for the Use of Dendrimers in Medicine

Dendritic metal complexes for bioimaging. Recent advances

Contact Info

Product

Resources

About